If this message is not displayed correctly, click here.

EDITOR IN CHIEF: Davide Bolignano

EDITORIAL BOARD: click here for the complete list

NEWSLETTER DESIGN: Francesca Trebelli

Summary Reports from 56^th ERA-EDTA Congress

New insights into pathogenesis and treatment of vascular calcification

Presented by Catherine Shanahan

Patients with chronic kidney disease (CKD) develop accelerated vascular calcification, predominantly of the vessel media where the entire vascular smooth muscle cell (VSMC) layer is covered in calcium and phosphate crystals, that is a major cause of cardiovascular mortality. This form is also present in patients with diabetes and in aged individuals. Another form, intimal calcification, is associated with atherosclerosis and it is a strong indicator of cardiovascular mortality, regardless of its location in the body. In the past, vascular calcification was considered a degenerative age-associated phenotype and an unmodifiable risk factor.

Biologic therapy in lupus nephritis – where are we now?

Presented by Gabriella Moroni

Owing to the improvement in the standard of care therapy for the most severe forms of lupus nephritis (LN), long-time renal survival has continuously improved[1], and the clinical presentation of LN has become less severe [2]. Despite these facts, renal damage is still the most important predictor of mortality within the damage index [3].

Personalized diagnosis and CKD prediction in genetic tubular disorders

Presented by Francesca Becherucci

Inherited tubulopathies represent a cluster of specific disorders caused by the genetic dysfunction of specialized transporters and channels expressed in the renal tubule. Inherited tubulopathies are rare diseases usually following Mendelian patterns of inheritance. Many are mono- or oligogenic disorders affecting children, but cases are not restricted to pediatrics and diagnosis may be delayed until adulthood. According to the main clinical picture, inherited tubulopathies can be classified in proximal tubule diseases; sodium and water reabsorption disorders (i.e. salt-losing tubulopathies); and renal tubular acidosis.

FOLLOW US

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the EU General Data Protection Regulation (2016/679). Unsubscribe